Molecular Imaging and Molecular Imaging Technologies
暂无分享,去创建一个
Jan Grimm | Katja Haedicke | Susanne Kossatz | Thomas Reiner | T. Reiner | J. Grimm | S. Kossatz | Katja Haedicke
[1] N. Dowson,et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. , 2015, Seminars in nuclear medicine.
[2] S. Groshen,et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. , 2014, American journal of nuclear medicine and molecular imaging.
[3] H. Herzog,et al. SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] Sanjiv S Gambhir,et al. A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.
[5] Sven N Reske,et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.
[6] S S Gambhir,et al. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] S. Venneti,et al. Non-invasive metabolic imaging of brain tumours in the era of precision medicine , 2016, Nature Reviews Clinical Oncology.
[8] D. Podoloff,et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.
[10] Gerald Antoch,et al. False-Positive FDG PET Uptake−the Role of PET/CT , 2006, European Radiology.
[11] M. Fjällskog,et al. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors , 2003, Medical oncology.
[12] M. P. Buchin,et al. Performance Parameters of a Positron Imaging Camera , 1976, IEEE Transactions on Nuclear Science.
[13] J. Kotzerke,et al. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Sameer Bansilal,et al. Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.
[15] Chun Li,et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.
[16] W. D. Mcelroy,et al. Crystalline firefly luciferase. , 1956, Biochimica et biophysica acta.
[17] Anna M. Wu,et al. Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.
[18] R. Boellaard,et al. 18F-FDG PET as a Tool to Predict the Clinical Outcome of Infliximab Treatment of Rheumatoid Arthritis: An Explorative Study , 2011, The Journal of Nuclear Medicine.
[19] David M. Wilson,et al. Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. , 2014, Chemical Society reviews.
[20] R. Miralbell,et al. Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[21] S. Schulz,et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. , 2008, The Journal of clinical endocrinology and metabolism.
[22] Xiaoyuan Chen,et al. Design and development of molecular imaging probes. , 2010, Current topics in medicinal chemistry.
[23] E E de Lange,et al. MR imaging and spectroscopy using hyperpolarized 129Xe gas: Preliminary human results , 1997, Magnetic resonance in medicine.
[24] A. Nunn,et al. Can receptors be imaged with MRI agents? , 1997, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[25] Hua Ai,et al. Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. , 2014, Current opinion in pharmacology.
[26] S. Lapi,et al. Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use , 2013, The Journal of Nuclear Medicine.
[27] À. Rovira,et al. Proton MR Spectroscopy Improves Discrimination between Tumor and Pseudotumoral Lesion in Solid Brain Masses , 2009, American Journal of Neuroradiology.
[28] F. Stuart Foster,et al. Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis , 2007, Molecular imaging.
[29] H. Stephan,et al. Nuclear and optical dual-labelled imaging agents , 2016, Nuklearmedizin.
[30] Mitchel S Berger,et al. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. , 2016, Journal of neurosurgery.
[31] A. Nechansky. HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. , 2010, Journal of pharmaceutical and biomedical analysis.
[32] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[33] David W Townsend,et al. PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] S. Srivastava,et al. Technetium-99m: an historical perspective. , 1982, The International journal of applied radiation and isotopes.
[35] A. Alavi,et al. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[36] Cassius Vinicius Stevani,et al. Firefly Luminescence: a Historical Perspective and Recent Developments the Structural Origin and Biological Function of Ph-sensitivity in Firefly Luciferases Activity Coupling and Complex Formation between Bacterial Luciferase and Flavin Reductases Coelenterazine-binding Protein of Renilla Muelleri: , 2022 .
[37] E. R. Andrew. Nuclear magnetic resonance and the brain , 2005, Brain Topography.
[38] I. Donald,et al. Investigation of abdominal masses by pulsed ultrasound. , 1958, Lancet.
[39] Jan Grimm,et al. Cerenkov imaging. , 2014, Advances in cancer research.
[40] P. Blower,et al. Hypoxia imaging with PET: which tracers and why? , 2012, Nuclear medicine communications.
[41] S. Batra,et al. Recent trends in antibody-based oncologic imaging. , 2012, Cancer letters.
[42] Erlong Zhang,et al. A review of NIR dyes in cancer targeting and imaging. , 2011, Biomaterials.
[43] Zhigang Wang,et al. Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[44] S. Meikle,et al. Small animal SPECT and its place in the matrix of molecular imaging technologies , 2005, Physics in medicine and biology.
[45] P. Kuo. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. , 2008, Journal of the American College of Radiology : JACR.
[46] D. Vriens,et al. Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review , 2009, Journal of Nuclear Medicine.
[47] R. Bradley,et al. A review of attenuation correction techniques for tissue fluorescence , 2006, Journal of The Royal Society Interface.
[48] G. V. van Dongen,et al. Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.
[49] Byung-Tae Kim,et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. , 2005, Radiology.
[50] J. Vercher-Conejero,et al. Clinical oncologic applications of PET/MRI: a new horizon. , 2014, American journal of nuclear medicine and molecular imaging.
[51] S. Ramin,et al. Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.
[52] Ulrich B Wiesner,et al. Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. , 2016, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[53] H. Dittmann,et al. [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[54] M. Thaning,et al. Real-time metabolic imaging. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[55] Y. Akagi,et al. Navigation surgery for intraoperative sentinel lymph node detection using Indocyanine green (ICG) fluorescence real-time imaging in breast cancer , 2015, Breast Cancer Research and Treatment.
[56] David A. Mankoff,et al. PET/CT imaging in cancer: Current applications and future directions , 2014, Cancer.
[57] Ora Israel,et al. Cancer Recurrence: Diagnostic Value and Impact on Patient Management , 2004 .
[58] H. Steinert,et al. Single-photon emission computed tomography/computed tomographyfor sentinel node mapping in breast cancer. , 2007, Seminars in nuclear medicine.
[59] Sarah E Bohndiek,et al. Contrast agents for molecular photoacoustic imaging , 2016, Nature Methods.
[60] P. Lauterbur,et al. Image Formation by Induced Local Interactions: Examples Employing Nuclear Magnetic Resonance , 1973, Nature.
[61] M. Frydenberg,et al. Investigations with FDG-PET Scanning in Prostate Cancer Show Limited Value for Clinical Practice , 2002, Acta oncologica.
[62] W. Oyen,et al. Radiolabelled peptides for oncological diagnosis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[63] Joong-Won Park,et al. [Diagnostic accuracy of 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma]. , 2006, The Korean journal of hepatology.
[64] P. Larson,et al. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.
[65] Joshua S Richman,et al. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.
[66] L. Kemna,et al. Iodine-123 α-methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent , 1998, European Journal of Nuclear Medicine.
[67] M. Ferrari,et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[68] J S Petersson,et al. Molecular imaging using hyperpolarized 13C. , 2003, The British journal of radiology.
[69] U. Haberkorn,et al. [18F]FLT; portrait of a proliferation marker. , 2002, European journal of nuclear medicine and molecular imaging.
[70] R. Clarkson. Blood-Pool MRI Contrast Agents: Properties and Characterization , 2002 .
[71] S. Singhal,et al. Identification of breast cancer margins using intraoperative near‐infrared imaging , 2016, Journal of surgical oncology.
[72] M. Muzi,et al. Applications of PET imaging with the proliferation marker [18F]-FLT. , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[73] A. Drzezga,et al. First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses , 2012, The Journal of Nuclear Medicine.
[74] O. Shimomura,et al. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. , 1962, Journal of cellular and comparative physiology.
[75] Yun Sun,et al. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles. , 2011, Biomaterials.
[76] H. Groen,et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] A. Scarsbrook,et al. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. , 2008, Clinical radiology.
[78] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[79] T. Holland-Letz,et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[80] E. Sorantin,et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging , 2008, Nuklearmedizin.
[81] Jonathan M. Links,et al. Imaging dopamine receptors in the human brain by positron tomography , 1983 .
[82] Sarah E Bohndiek,et al. Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.
[83] A. Alavi,et al. Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. , 1977, Acta neurologica Scandinavica. Supplementum.
[84] M. Renz. Fluorescence microscopy—A historical and technical perspective , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[85] W. Schima,et al. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications , 2004, European Radiology.
[86] S R Cherry,et al. Optical imaging of Cerenkov light generation from positron-emitting radiotracers , 2009, Physics in medicine and biology.
[87] W. Moses. Fundamental Limits of Spatial Resolution in PET. , 2011, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.
[88] Vasilis Ntziachristos,et al. Looking and listening to light: the evolution of whole-body photonic imaging , 2005, Nature Biotechnology.
[89] V. Grégoire,et al. A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[90] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[91] A. Grichine,et al. Reply to: Comments on 'Intraoperative near-infrared fluorescence imaging using indocyanine green in colorectal carcinomatosis surgery: Proof of concept'. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[92] Jan Henrik Ardenkjaer-Larsen,et al. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. , 2006, Cancer research.
[93] Wolfgang A. Weber,et al. O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.
[94] Monique R Bernsen,et al. Computed tomography and magnetic resonance imaging. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[95] E. Krenning,et al. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. , 2011, Seminars in nuclear medicine.
[96] P. Metellus,et al. 5-Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review. , 2016, Advances and technical standards in neurosurgery.
[97] M Goldsmith,et al. NMR in cancer: XVI. FONAR image of the live human body. , 1977, Physiological chemistry and physics.
[98] Minyong Li,et al. Cage the firefly luciferin! - a strategy for developing bioluminescent probes. , 2013, Chemical Society reviews.
[99] M P Sandler,et al. FDG-SPECT: correlation with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[100] T. Holland-Letz,et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[101] Cristina Martelli,et al. Optical imaging probes in oncology , 2016, Oncotarget.
[102] Jan Grimm,et al. Clinical Cerenkov Luminescence Imaging of 18F-FDG , 2014, The Journal of Nuclear Medicine.
[103] M S Rosenthal,et al. Quantitative SPECT imaging: a review and recommendations by the Focus Committee of the Society of Nuclear Medicine Computer and Instrumentation Council. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[104] Yi-Xiang J. Wang. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. , 2011, Quantitative imaging in medicine and surgery.
[105] M. Blaufox,et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases , 2005, Breast Cancer Research and Treatment.
[106] R. Weissleder,et al. Molecular imaging of gene therapy for cancer , 2004, Gene Therapy.
[107] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[108] J. Mukherjee,et al. 11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.
[109] J. Pinski,et al. FDG PET in suspected recurrent and metastatic prostate cancer. , 2003, Oncology reports.
[110] H. Jun,et al. Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. , 2010, Academic radiology.
[111] A. Grichine,et al. Intraoperative Near-Infrared Fluorescence Imaging using indocyanine green in colorectal carcinomatosis surgery: Proof of concept. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[112] L. Jeng,et al. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. , 2012, European journal of radiology.
[113] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[114] T. Etrych,et al. Fluorescence optical imaging in anticancer drug delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[115] Greg M. Thurber,et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.
[116] Jan Wolber,et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.
[117] R. Wahl,et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[118] S. Vallabhajosula. Molecular Imaging: Radiopharmaceuticals for PET and SPECT , 2009 .
[119] A. Alavi,et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[120] Christos Davatzikos,et al. Imaging genomics in cancer research: limitations and promises. , 2016, The British journal of radiology.
[121] W. Edelstein,et al. The intrinsic signal‐to‐noise ratio in NMR imaging , 1986, Magnetic resonance in medicine.
[122] J. Moretti,et al. Clinical validation of simultaneous dual-isotope myocardial scintigraphy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[123] Zhi-Yi Chen,et al. Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosis , 2010, Journal of experimental & clinical cancer research : CR.
[124] Paul M. Parizel,et al. Clinical MR imaging , 1999 .
[125] I. Nöbauer-Huhmann,et al. The optimal use of contrast agents at high field MRI , 2006, European Radiology.
[126] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[127] Konstantin Nikolaou,et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives , 2016, Advances in Therapy.
[128] G. Chiro. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .
[129] R. Weissleder,et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. , 2012, Neoplasia.
[130] W. Oyen,et al. Fluorinated amino acids for tumour imaging with positron emission tomography , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[131] K. Kubota,et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints , 2009, Annals of nuclear medicine.
[132] W. Oyen,et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[133] Robert A. deKemp,et al. The Use of 18F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience , 2012, The Journal of Nuclear Medicine.
[134] Young‐Tae Chang,et al. A macrophage-specific fluorescent probe for intraoperative lymph node staging. , 2014, Cancer research.
[135] Jan Grimm,et al. Positron Lymphography: Multimodal, High-Resolution, Dynamic Mapping and Resection of Lymph Nodes After Intradermal Injection of 18F-FDG , 2012, The Journal of Nuclear Medicine.
[136] C. Claussen,et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. , 2004, AJR. American journal of roentgenology.
[137] E. Chekmenev,et al. Low-field MRI can be more sensitive than high-field MRI. , 2013, Journal of magnetic resonance.
[138] P. Low,et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.
[139] G. V. van Dongen,et al. The promise of immuno-PET in radioimmunotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[140] Johannes A Langendijk,et al. PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.
[141] R. Hustinx,et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[142] E. Krenning,et al. Somatostatin receptor imaging. , 2002, Seminars in nuclear medicine.
[143] H. Weinmann,et al. First use of GdDTPA/dimeglumine in man. , 1984, Physiological chemistry and physics and medical NMR.
[144] F Dehdashti,et al. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[145] T. Hara,et al. PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[146] Thomas Beyer,et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] Carlo Cavedon,et al. First human Cerenkography , 2013, Journal of biomedical optics.
[148] E. Krenning,et al. Somatostatin receptor imaging for neuroendocrine tumors , 2006, Pituitary.
[149] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[150] Jan Grimm,et al. Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions , 2011, Molecular imaging.
[151] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[152] W Vaalburg,et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[153] F. Korosec,et al. Functional lung imaging using hyperpolarized gas MRI , 2007, Journal of magnetic resonance imaging : JMRI.
[154] J. Kurhanewicz,et al. Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. , 2013, Cancer research.
[155] S. Larson,et al. Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. , 2010, Gynecologic oncology.
[156] E. Even-Sapir. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[157] Michael Sabel,et al. Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[158] Dale L. Bailey,et al. Quantitative SPECT/CT: SPECT joins PET as a quantitative imaging modality , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[159] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[160] D. Matchar,et al. FDG-PET for management of cervical and ovarian cancer. , 2005, Gynecologic oncology.
[161] S. Schoenberg,et al. High-Resolution Whole-Body Magnetic Resonance Image Tumor Staging With the Use of Parallel Imaging Versus Dual-Modality Positron Emission Tomography–Computed Tomography: Experience on a 32-Channel System , 2005, Investigative radiology.
[162] Gerald Reischl,et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[163] J. M. Udias,et al. Simulation of triple coincidences in PET , 2013, 2013 IEEE Nuclear Science Symposium and Medical Imaging Conference (2013 NSS/MIC).
[164] V. Ntziachristos. Fluorescence molecular imaging. , 2006, Annual review of biomedical engineering.
[165] Aaron M Mohs,et al. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential , 2007, Expert opinion on drug delivery.
[166] Fabian Kiessling,et al. Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery , 2015, Front. Pharmacol..
[167] Marie-France Bellin,et al. Extracellular gadolinium-based contrast media: an overview. , 2008, European journal of radiology.
[168] Massoud Motamedi,et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[169] Ciprian Catana,et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging , 2008, Nature Medicine.
[170] G. Moore,et al. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. , 1948, Journal of neurosurgery.
[171] A. Constantinesco,et al. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[172] Sam SIDDIGHI,et al. Indocyanine green for intraoperative localization of ureter. , 2014, American journal of obstetrics and gynecology.
[173] Sven Perner,et al. Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[174] G. Denardo,et al. Trials and tribulations: oncological antibody imaging comes to the fore. , 1997, Seminars in nuclear medicine.
[175] K Kubota,et al. From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology , 2001, Annals of nuclear medicine.
[176] Jennifer A. Prescher,et al. Bioluminescence: a versatile technique for imaging cellular and molecular features. , 2014, MedChemComm.
[177] Eduardo Schiffer,et al. Intra‐operative fluorescent cholangiography using indocyanin green during robotic single site cholecystectomy , 2012, The international journal of medical robotics + computer assisted surgery : MRCAS.
[178] Wolfgang A Weber,et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.
[179] M. Reiser,et al. Whole-body MRI for the staging and follow-up of patients with metastasis. , 2009, European journal of radiology.
[180] L. Bachmann,et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.
[181] G. Treglia,et al. Usefulness of 11C-Methionine Positron Emission Tomography in Differential Diagnosis between Recurrent Tumours and Radiation Necro-sis in Patients with Glioma: An Overview , 2012 .
[182] M. Shibutani,et al. Preferential tumor cellular uptake and retention of indocyanine green for in vivo tumor imaging , 2016, International journal of cancer.
[183] R. Weissleder,et al. Imaging in the era of molecular oncology , 2008, Nature.
[184] Jan Grimm,et al. Cerenkov Luminescence Imaging of Medical Isotopes , 2010, Journal of Nuclear Medicine.
[185] H. Carmalt,et al. SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. , 2012, Breast.
[186] R. Weissleder,et al. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.
[187] S S Gambhir,et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[188] E. Krenning,et al. Octreoscan radioreceptor imaging , 2003, Endocrine.
[189] J. Mansfield,et al. Distinguished photons: a review of in vivo spectral fluorescence imaging in small animals. , 2010, Current pharmaceutical biotechnology.
[190] David A Mankoff,et al. A definition of molecular imaging. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[191] R. Jones,et al. Immunological Properties of an Antibody Containing a Fluorescent Group.∗ , 1941 .
[192] R. Q. Edwards,et al. The Mark IV system for radionuclide computed tomography of the brain. , 1976, Radiology.
[193] R. Boellaard. Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.
[194] Boyd M. Goodson. Nuclear magnetic resonance of laser-polarized noble gases in molecules, materials, and organisms. , 2002 .
[195] Jonathan F. Lovell,et al. Porphyrins as Theranostic Agents from Prehistoric to Modern Times , 2012, Theranostics.
[196] A. D’Amico,et al. A Brief History of Active Sonar , 2009 .
[197] K Kirk Shung,et al. High Frequency Ultrasonic Imaging. , 2009, Journal of medical ultrasound.
[198] R Weissleder,et al. Near-infrared optical imaging of protease activity for tumor detection. , 1999, Radiology.
[199] Bruce D Cheson,et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.
[200] Arion F. Chatziioannou,et al. Molecular imaging of small animals with dedicated PET tomographs , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[201] Graham M. Treece,et al. Three-dimensional ultrasound imaging , 2010, Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine.
[202] Samuel Achilefu,et al. Optical Imaging in Cancer Research: Basic Principles, Tumor Detection, and Therapeutic Monitoring , 2011, Medical Principles and Practice.
[203] Barry H. Smith,et al. 18F-2-FLUORO-2-DEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY OF HUMAN CEREBRAL GLIOMAS , 1981 .
[204] Rajiv Gupta,et al. Advances in computed tomography imaging technology. , 2014, Annual review of biomedical engineering.
[205] Kevin M Brindle,et al. Imaging tumour cell metabolism using hyperpolarized 13C magnetic resonance spectroscopy. , 2010, Biochemical Society transactions.
[206] D. Patton. The birth of nuclear medicine instrumentation: Blumgart and Yens, 1925. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[207] M. Nicolson,et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer , 1998, The British journal of surgery.
[208] Yajing Liu,et al. Photoacoustic Molecular Imaging: From Multiscale Biomedical Applications Towards Early-Stage Theranostics. , 2016, Trends in biotechnology.
[209] F. Kiessling,et al. Targeted ultrasound imaging of cancer: an emerging technology on its way to clinics. , 2012, Current pharmaceutical design.
[210] Douglas A Levine,et al. Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. , 2014, Gynecologic oncology.
[211] Joaquin L. Herraiz,et al. Recovery and normalization of triple coincidences in PET. , 2015, Medical physics.
[212] Ludwig G. Strauss,et al. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.
[213] Y. Dohi,et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. , 2004, Chest.
[214] M. Albert,et al. Development of hyperpolarized noble gas MRI. , 1998, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.
[215] J. Capala,et al. The role of nuclear medicine in modern therapy of cancer , 2012, Tumor Biology.
[216] Thomas Beyer,et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[217] Tingting Xu,et al. In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals , 2010, Sensors.
[218] Leif Østergaard,et al. Final infarct size after acute stroke: prediction with flow heterogeneity. , 2002, Radiology.
[219] N. Sadato,et al. 11C-acetate PET imaging of prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[220] M. Reivich,et al. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose , 1978 .
[221] Z. Bhujwalla,et al. Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.
[222] J. Reubi,et al. Peptide-Based Probes for Cancer Imaging , 2008, Journal of Nuclear Medicine.
[223] A. Drzezga,et al. Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[224] P. Curie,et al. Développement par compression de l'électricité polaire dans les cristaux hémièdres à faces inclinées , 1880 .
[225] Stefano Fanti,et al. The clinical use of PET with (11)C-acetate. , 2012, American journal of nuclear medicine and molecular imaging.
[226] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[227] Wolfgang Uter,et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.
[228] A. Alavi,et al. The [18F]Fluorodeoxyglucose Method for the Measurement of Local Cerebral Glucose Utilization in Mane , 1979, Circulation research.
[229] Thomas C. Kwee,et al. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis , 2008, European Radiology.
[230] Y. Yonekura,et al. A strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L-tyrosine. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[231] H C Charles,et al. Human lung air spaces: potential for MR imaging with hyperpolarized He-3. , 1996, Radiology.
[232] S S Gambhir,et al. A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[233] Sanjiv S Gambhir,et al. Reporter gene imaging of protein-protein interactions in living subjects. , 2007, Current opinion in biotechnology.
[234] K. Chuang,et al. Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis. , 2013, Journal of healthcare engineering.
[235] G. Radda,et al. Molecular imaging perspectives , 2005, Journal of The Royal Society Interface.
[236] Thomas E Yankeelov,et al. MR Imaging Biomarkers in Oncology Clinical Trials. , 2016, Magnetic resonance imaging clinics of North America.
[237] E. Krenning,et al. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results , 2017, The Journal of Nuclear Medicine.
[238] E. N. Harvey,et al. A History of Luminescence: From the Earliest Times Until 1900 , 2005 .
[239] M. Khalil,et al. Molecular SPECT Imaging: An Overview , 2011, International journal of molecular imaging.
[240] Jochen Herms,et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[241] R. Schibli,et al. Versatile routes to C-2- and C-6-functionalized glucose derivatives of iminodiacetic acid. , 2003, The Journal of organic chemistry.
[242] W. Schultze‐Seemann,et al. GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences , 2014 .
[243] T. Budinger,et al. NMR of laser-polarized xenon in human blood. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[244] Siavash Yazdanfar,et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met , 2015, Nature Medicine.
[245] R Myers,et al. The biological application of small animal PET imaging. , 2001, Nuclear medicine and biology.
[246] Vasilis Ntziachristos,et al. Advancing Surgical Vision with Fluorescence Imaging. , 2016, Annual review of medicine.
[247] D. Kacher,et al. Hyperpolarized 129Xe MR imaging of the oral cavity. , 1996, Journal of magnetic resonance. Series B.
[248] Jorge Ripoll,et al. Advances in optical imaging for pharmacological studies , 2015, Front. Pharmacol..
[249] A. Rosato,et al. Optical and multimodal peptide-based probes for in vivo molecular imaging. , 2012, Anti-cancer agents in medicinal chemistry.
[250] S. -O. Bohman,et al. GLOMERULAR CRESCENT CELLS , 1976, The Lancet.
[251] S. Lamberts,et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.
[252] Jianlin Yuan,et al. Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field , 2014, International journal of nanomedicine.
[253] V. Ntziachristos,et al. Molecular imaging by means of multispectral optoacoustic tomography (MSOT). , 2010, Chemical reviews.
[254] E. Hoffman,et al. A positron-emission transaxial tomograph for nuclear imaging (PETT). , 1975, Radiology.
[255] Ralph Weissleder,et al. Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.
[256] L. Sorensen,et al. VISUALIZATION OF THE LIVER BY SCANNING WITH MO99 (MOLYBDATE) AS TRACER. , 1963, The Journal of laboratory and clinical medicine.
[257] Yin Zhang,et al. PET tracers based on Zirconium-89. , 2011, Current radiopharmaceuticals.
[258] D W Townsend,et al. Physical principles and technology of clinical PET imaging. , 2004, Annals of the Academy of Medicine, Singapore.
[259] J. Mehrkens,et al. The positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment , 2008, Journal of Neuro-Oncology.
[260] M. Neurath,et al. Endomicroscopic Imaging of COX-2 Activity in Murine Sporadic and Colitis-Associated Colorectal Cancer , 2013, Diagnostic and therapeutic endoscopy.